drugset / Trial / NCT06290349
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
RandomizedParallel-groupDouble-blindTreatment
Summary
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose control. The study focuses on assessing the effectiveness and safety of the triple combination therapy.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2025-09-05
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA5221-T1 | Unknown | — | Oral |
| Subject | DA5221-T2 | Unknown | — | Oral |
| Background | DA5221-B1 | Unknown | — | Oral |
| Background | DA5221-B2 | Unknown | — | Oral |